Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have received a consensus recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $30.00.

Several analysts recently issued reports on the stock. HC Wainwright upped their price objective on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Chardan Capital restated a “buy” rating and set a $27.00 price target on shares of Eyepoint Pharmaceuticals in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th. Mizuho set a $28.00 price objective on Eyepoint Pharmaceuticals in a research report on Monday, October 20th. Finally, Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of EYPT. Adage Capital Partners GP L.L.C. boosted its holdings in Eyepoint Pharmaceuticals by 9.7% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company’s stock valued at $63,988,000 after purchasing an additional 600,000 shares during the period. Federated Hermes Inc. raised its position in shares of Eyepoint Pharmaceuticals by 12.6% during the second quarter. Federated Hermes Inc. now owns 4,599,450 shares of the company’s stock valued at $43,281,000 after buying an additional 513,870 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 3.6% in the second quarter. Franklin Resources Inc. now owns 4,301,123 shares of the company’s stock valued at $40,474,000 after buying an additional 151,262 shares during the period. Vanguard Group Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 0.8% in the first quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company’s stock valued at $20,782,000 after buying an additional 31,141 shares during the period. Finally, Paradigm Biocapital Advisors LP acquired a new stake in Eyepoint Pharmaceuticals during the third quarter worth about $28,556,000. Institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Performance

EYPT opened at $13.69 on Wednesday. The company has a market cap of $1.13 billion, a PE ratio of -4.58 and a beta of 1.67. The stock has a 50-day moving average of $12.92 and a 200-day moving average of $11.16. Eyepoint Pharmaceuticals has a 52-week low of $3.91 and a 52-week high of $14.96.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 76.13% and a negative net margin of 485.95%.The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $3.33 million. On average, research analysts predict that Eyepoint Pharmaceuticals will post -2.13 earnings per share for the current year.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.